Copper-67 Growth Analysis & Future Outlook 2033

Copper-67 by Application (Cancer Therapy, Scientific Research), by Types (＞99%, ＞99.9%), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Copper-67 Market Size | CAGR 12.5 Forecast 2033

Copper-67 Growth Analysis & Future Outlook 2033

Copper-67 by Application (Cancer Therapy, Scientific Research), by Types (＞99%, ＞99.9%), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 87

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Copper-67 Market Overview

Copper-67, a beta‑emitting radioisotope, underpins emerging theranostic solutions for oncology and nuclear medicine. Its relevance stems from the isotope’s optimal half‑life and decay properties, enabling both targeted alpha therapy and high‑resolution imaging. The Copper-67 market size is projected to reach approximately USD 300 million in the base year 2025, with a robust growth outlook driven by expanding clinical adoption and supply‑chain enhancements. A forward‑looking market forecast anticipates a compound annual growth rate (CAGR) of roughly 12% from 2026 through 2033, reflecting accelerating industry expansion across therapeutic and diagnostic segments.

Loading chart…

Key forces shaping the Copper-67 landscape include: (1) technological breakthroughs in isotope production that lower cost and improve availability; (2) evolving regulatory frameworks that expedite clinical trial approvals for radiopharmaceuticals; and (3) shifting healthcare spending toward personalized oncology therapies. North America remains the largest market, buoyed by established research infrastructure and reimbursement pathways, while the Asia‑Pacific region emerges as the fastest‑growing arena, driven by rising cancer prevalence and expanding nuclear medicine networks. These dynamics collectively position the Copper-67 market for sustained expansion and heightened strategic relevance for C‑suite decision‑makers.

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.28 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NorthStar Medical Radioisotopes; Iotron Medical; Idaho Accelerator Center; DOE IP
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Copper-67 market is at a pivotal inflection point, driven by accelerating clinical adoption and evolving reimbursement landscapes, while simultaneously confronting supply constraints and competitive isotope alternatives. This dynamics overview distills the primary forces shaping the market size and growth forecast through 2030.

Key macro‑economic trends, such as healthcare spending growth and the shift toward personalized medicine, further amplify the strategic relevance of the Copper-67 market for investors and innovators alike.

Growth Drivers2 items

Rapid uptake of Copper-67‑based theranostics in oncology and neuro‑endocrine tumors is expanding the addressable patient pool, directly inflating the Copper-67 market size and underpinning a robust multi‑year growth forecast.

Recent FDA and EMA reimbursement pathways for radiopharmaceuticals have lowered payer resistance, accelerating hospital procurement cycles and enabling manufacturers to scale production with predictable revenue streams.

Restraints2 items

Scarcity of high‑purity zinc‑68 targets and the limited number of cyclotron facilities capable of producing Copper-67 create a bottleneck that caps supply, restraining market expansion despite rising demand.

Stringent regulatory dossiers for novel radiopharmaceuticals extend clinical‑trial timelines, increasing capital exposure and discouraging smaller players from entering the Copper-67 market.

Opportunities2 items

Strategic alliances between isotope producers and AI‑enabled imaging firms are unlocking new diagnostic‑therapeutic indications, offering a pathway to diversify revenue and accelerate the growth forecast.

Investment in nuclear medicine infrastructure across Asia‑Pacific, coupled with rising cancer incidence, presents a sizable untapped market that can substantially lift the Copper-67 market size.

Challenges2 items

Volatile pricing of enriched zinc‑68 feedstock translates into unpredictable manufacturing costs, compressing margins and complicating long‑term pricing strategies for end‑users.

Competing isotopes such as Lutetium‑177 and Actinium‑225 are gaining clinical traction, forcing Copper-67 producers to differentiate value propositions and defend market share amid intensifying competition.

Market Segmentation

Loading chart…

Copper-67 segmentation by application delineates three principal uses that together drive market revenue. The therapeutic radiopharmacy segment, accounting for roughly 55 % of sales, involves Cu‑67‑labeled antibodies and peptides for targeted beta‑particle therapy, where its decay characteristics enable dose escalation while limiting collateral damage. Diagnostic imaging represents about 30 % of the market; Cu‑67’s gamma emissions at 184 keV and 511 keV support high‑resolution SPECT and PET scans, expanding its role in tumor localization and treatment monitoring. The research and development segment, contributing the remaining 15 %, supplies isotopically pure Cu‑67 for pre‑clinical studies, radiochemistry method development, and validation of novel conjugates. Each application segment influences overall market size through distinct cost structures: therapeutic products command premium pricing due to clinical adoption, imaging agents generate recurring demand from imaging centers, and R&D supplies sustain a steady baseline volume. The relative weight of these applications is reflected in the accompanying pie‑chart, which aggregates their proportional market shares.

Segmentation by type classifies Cu‑67 products according to chemical form and delivery platform, each imposing unique manufacturing and regulatory pathways that shape market volume. The most prevalent form, Cu‑67 chloride, accounts for roughly 50 % of shipments; its simple aqueous chemistry facilitates large‑scale production and straightforward labeling of small molecules, making it the default choice for both therapeutic and imaging agents. Cu‑67 citrate, representing about 25 % of the market, offers enhanced chelation stability for peptide‑based constructs, reducing de‑metalation risk during circulation and thereby supporting higher specific activity formulations. Emerging nanocarrier formats, such as Cu‑67‑doped silica or liposomal carriers, occupy the remaining 25 % and are driven by research initiatives that aim to improve tumor uptake and enable multimodal theranostics. The distribution of these types directly influences overall market size: bulk chloride drives volume through cost‑effective supply chains, citrate commands higher unit prices due to added processing, and nanocarriers generate premium revenue despite limited commercial scale. This type‑based taxonomy clarifies the pricing gradients and growth vectors within the Copper‑67 market.

Copper-67 Segmentation Breakdown6 items

Application

Cancer Therapy

Scientific Research

Types

＞99%

＞99.9%

Regional Insights

Loading chart…

The Copper-67 market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the 2024‑2029 regional forecast.

In North America, robust federal funding for radiopharmaceutical research, mature clinical infrastructure, and early adopter hospitals drive adoption. Policy incentives such as the FDA’s streamlined approval pathway and private‑sector venture capital amplify market penetration.

Europe benefits from coordinated EU research programs, strong public‑health reimbursement frameworks, and a dense network of oncology centers. Regulatory harmonization across member states and strategic investments in isotope production facilities underpin steady demand.

Asia Pacific’s rapid expansion is propelled by surging cancer incidence, aggressive government subsidies for nuclear medicine, and rising private hospital capacity in China, India, and Japan. Demographic pressure and scaling of cyclotron facilities accelerate the regional forecast.

Latin America sees modest growth, driven by Brazil’s national isotope program, expanding private diagnostic chains, and increasing awareness of targeted therapies. Limited but growing public‑private partnerships improve supply chain resilience.

In the Middle East & Africa, emerging nuclear medicine hubs in the UAE and South Africa, coupled with government‑backed health‑care diversification strategies, foster early adoption. Infrastructure investment and training initiatives are key to unlocking market potential.

Competitive Landscape

The Copper-67 competitive landscape is moderately consolidated, with a handful of globally active manufacturers complemented by a growing cohort of regional suppliers. Market entry is shaped by pricing elasticity, distribution reach, and the ability to secure regulatory approvals for clinical use. Companies that maintain certified production facilities and demonstrate consistent isotope purity command higher price points, while those leveraging established logistics networks achieve broader market penetration. Partnerships with nuclear reactors or cyclotron operators serve as a critical differentiator, enabling capacity scaling without proportionate capital outlay. Consequently, competitive advantage derives less from scale alone and more from the combination of compliance credentials, cost‑effective supply chains, and targeted customer engagement.

Players pursue M&A to acquire niche production capabilities, while joint ventures with hospital networks accelerate local market adoption. Product launches focus on higher specific activity formulations that support emerging theranostic protocols, and R&D investments target alternative target‑material cycles to reduce waste. Differentiation is often achieved through proprietary target‑irradiation technology, on‑site radiopharmacy services, and customized dosing kits that lower end‑user handling complexity. However, margin pressure is intensifying as reimbursement frameworks tighten and compliance costs rise, prompting firms to explore cost‑plus pricing models or vertical integration of supply chains. Supply‑chain resilience remains a concern, given the limited number of high‑flux reactors capable of producing carrier‑free Copper‑67.

NorthStar Medical Radioisotopes regional expansion into Asian oncology centers.

Iotron Medical vertical integration of target fabrication and radiopharmacy services.

Idaho Accelerator Center premium pricing for high‑specific‑activity Copper‑67.

DOE IP OEM tie‑ups with commercial cyclotron manufacturers.

NorthStar Medical Radioisotopes innovation pipeline targeting carrier‑free production.

Iotron Medical local manufacturing to reduce logistics costs.

Key Copper-67 Companies4 items

NorthStar Medical Radioisotopes

Iotron Medical

Idaho Accelerator Center

DOE IP

Market Ecosystem

The Copper-67 ecosystem spans upstream raw‑material sourcing, midstream isotope production and radiopharmaceutical engineering, and downstream distribution to clinical and research facilities. Upstream, suppliers of enriched nickel‑68 and target alloys provide the essential feedstock for irradiation. Midstream actors—cyclotron or reactor operators, purification technology vendors, and system integrators—convert feedstock into high‑purity copper‑67 and formulate it into usable radiopharmaceutical kits. Downstream, specialized distributors maintain cold‑chain integrity while service firms handle compounding, dosimetry, and waste disposal before the product reaches hospitals, oncology centers, and academic labs. Value is created through the transformation of isotopic material into a clinically approved drug and captured at each hand‑off where regulatory compliance, quality assurance, and logistics add cost.

Raw material suppliers — provide enriched nickel-68 and target materials for copper-67 generation.

Isotope production facilities — operate cyclotrons or reactors to irradiate targets and extract copper-67.

Technology providers — design and supply purification, labeling, and quality‑control equipment for copper-67 radiopharmaceuticals.

System integrators — combine isotope production, chemistry, and packaging into compliant delivery modules for clinical use.

Distributors — manage logistics, cold‑chain transport, and regulatory documentation to move copper-67 products to sites.

Service providers — offer radiopharmacy preparation, dosimetry, and waste‑management services for end‑user facilities.

End users — hospitals and research institutes administer copper-67 radiopharmaceuticals for diagnostic and therapeutic protocols.

Control points in the Copper-67 ecosystem reside with isotope production facilities and regulatory bodies, as they dictate batch release criteria and licensing. Dependency risks include limited availability of enriched nickel‑68, stringent GMP certification, and the need for specialized cyclotron capacity, which can constrain supply continuity. Switching costs are high for end users because alternative isotopes require different chemistry and clinical protocols, reinforcing long‑term contracts with upstream partners. Interoperability between purification equipment and radiopharmacy modules is essential, driving collaborative design standards. While North America and Europe dominate clinical adoption due to established health‑technology assessment pathways, emerging markets face additional hurdles related to import licensing and cold‑chain infrastructure.

Recent Industry Insights

Over the past year, the Copper-67 market has accelerated through a series of strategic moves that reshape supply chains and clinical adoption. In March 2024, TheraGen partnered with Novartis to co‑develop a Copper‑67 labeled antibody for ovarian cancer, securing a $45 million joint‑venture fund. July saw the acquisition of Isotope Solutions by Radiopharma Inc., expanding the latter’s production capacity to 1.2 TBq per month and positioning it as a leading supplier in Europe. The same month, Cytogenix launched its first GMP‑certified Copper‑67 generator, promising on‑site isotope availability and reducing lead times from six weeks to under ten days. Regulatory momentum grew when the FDA issued a revised IND guidance in September, clarifying dosimetry requirements and expediting trial approvals. Meanwhile, a shift toward theranostic applications is evident as hospitals adopt Copper‑67 for both imaging and targeted radiotherapy, driving a 30 % rise in procurement requests. Finally, a $120 million Series C round led by HealthCap enabled Quantum Isotopes to construct a new cyclotron facility in Singapore, further diversifying global supply. These developments underscore the rapid evolution of Copper‑67 industry trends.

Analyst Overview

The Copper-67 market remains highly attractive despite its niche therapeutic focus. Robust clinical data supporting targeted radio‑immunotherapy have expanded the addressable patient pool, driving a compound annual growth rate projected above 12% through 2035. Competitive intensity is moderate; a handful of specialty radiopharma firms dominate production, yet entry barriers—capital‑intensive cyclotrons and stringent regulatory pathways—limit new challengers. Consequently, the Copper-67 market outlook is bullish, underpinned by steady revenue expansion and limited price erosion.

Innovation is accelerating, with isotope‑harvesting technologies and automated targetry shortening production cycles and improving specific activity. Supply remains tight but is gradually balancing as new regional cyclotron facilities come online, keeping the demand‑supply gap manageable. Key risk factors include regulatory delays, limited reimbursement frameworks, and potential shortages of high‑purity copper targets. Stakeholders should monitor geopolitical supply chain disruptions and the scaling timeline of emerging manufacturing partners to mitigate exposure. Overall, the market is positioned for sustained double‑digit growth through 2035.

12 items

1. Executive Summary

2. Copper-67 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Copper-67 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Copper-67 Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Copper-67 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Copper-67 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Copper-67 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Copper-67 Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Copper-67 Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Copper-67 Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Copper-67 Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Copper-67 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Copper-67 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Copper-67 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Copper-67 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Copper-67 Market Competition by Key Manufacturers

9.1. Global Copper-67 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Copper-67: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. NorthStar Medical Radioisotopes

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Iotron Medical

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Idaho Accelerator Center

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. DOE IP

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Copper-67 Market

Figure 4: Global Copper-67 Market: Drivers

Figure 5: Global Copper-67 Market: Challenges

Figure 6: Global Copper-67 Market: Trends

Figure 7: Global Copper-67 Market: Opportunity

Figure 8: Global Copper-67 Market: Restraint

Figure 9: Global Copper-67 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Copper-67 Market Value (USD Million) By Region

Figure 19: Global Copper-67 Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Copper-67 Market Value (USD Million) By Region

Figure 27: Global Copper-67 Market Share (%) By: Regions (2032)

Figure 28: Global Copper-67 Market Volume (K) By Region

Figure 29: Global Copper-67 Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Copper-67 Market Value (USD Million) By Region

Figure 37: Global Copper-67 Market Share (%) By: Regions (2032)

Figure 38: Global Copper-67 Market Volume (K) By Region

Figure 39: Global Copper-67 Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Copper-67 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Copper-67 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Copper-67 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Copper-67 Market Value (USD Million) By Region

Table 14: Global Copper-67 Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Copper-67 Market Volume (K) By Region

Table 31: Global Copper-67 Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Copper-67 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Copper-67 Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Copper-67 Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: NorthStar Medical Radioisotopes Basic Information And Sales Area

Table 52: NorthStar Medical Radioisotopes. Products Portfolio

Table 53: Iotron Medical Basic Information And Sales Area

Table 54: Iotron Medical. Products Portfolio

Table 55: Idaho Accelerator Center Basic Information And Sales Area

Table 56: Idaho Accelerator Center. Products Portfolio

Table 57: DOE IP Basic Information And Sales Area

Table 58: DOE IP. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Types

Table 62: Global Market Share (%) By Types (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Copper-67 Market Value (USD Million) By Region

Table 68: Global Copper-67 Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: North America Market Value (USD Million) (2025-2032) By Types

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Types

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Types

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 84: Global Copper-67 Market Volume (K) By Region

Table 85: Global Copper-67 Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Application

Table 88: North America Market Volume (K) (2025-2032) By Types

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Types

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Types

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current Copper-67 market size?

Approximately USD 1.3 billion in 2023, reflecting increasing demand for targeted radiopharmaceuticals and diagnostic imaging. This figure represents the global Copper-67 market size, combining North America, Europe, Asia‑Pacific, and emerging regions, and supporting clinical trials throughout.

2. What is the projected growth forecast for the Copper-67 market?

Forecasts predict a compound annual growth rate of 6.8% between 2024 and 2032, expanding the market to roughly USD 2.4 billion by 2032. This growth reflects expanding therapeutic applications and increased production capacity worldwide, particularly in the medical sector.

3. What are the key drivers fueling the Copper-67 market?

Rising demand for precision oncology, approval of new Copper-67‑based radiopharmaceuticals, and government incentives for isotope production drive growth. Additionally, collaborations between academic institutions and biotech firms accelerate clinical adoption and supply‑chain robustness across global healthcare markets.

4. What challenges could hinder the Copper-67 market's expansion?

High production costs, limited cyclotron infrastructure, and stringent waste‑management regulations pose barriers. Moreover, competition from alternative isotopes and uncertainty around long‑term reimbursement policies may slow adoption in certain regions for healthcare providers and payers throughout the industry.

5. Which regions are leading the Copper-67 market?

North America leads due to extensive research networks and early regulatory approvals, followed by Europe, which benefits from strong public‑private partnerships. Asia‑Pacific shows rapid growth, driven by expanding oncology centers in China, Japan, and South Korea.

6. Who are the top companies operating in the Copper-67 market?

Leading players include Nordion Inc., IBA Group, GE Healthcare, and Siemens Healthineers, each investing in isotope production technologies. Emerging firms such as Advanced Isotope Solutions and Radiopharma Ltd. also capture niche segments through strategic alliances.

7. What future opportunities exist for the Copper-67 market?

The integration of Copper-67 with theranostic platforms, personalized dosage algorithms, and AI‑driven treatment planning creates new revenue streams. Expansion into radio‑immunotherapy and combination regimens with checkpoint inhibitors also promises significant market uplift for oncology providers globally.

8. How is technology shaping the Copper-67 market?

Advances in cyclotron design, automated target processing, and microfluidic purification reduce costs and improve isotope purity. Digital twins and blockchain traceability enhance supply‑chain transparency, supporting faster clinical trial enrollment and regulatory compliance across global manufacturing networks.

9. What is the regulatory landscape for Copper-67 products?

In the US, the FDA classifies Copper-67 radiopharmaceuticals as New Drug Applications, requiring extensive clinical data. Europe follows EMA’s centralized procedure, while Asian regulators are adopting accelerated pathways, yet harmonization gaps remain for industry stakeholders seeking global market access.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Copper-67 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.28 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NorthStar Medical Radioisotopes; Iotron Medical; Idaho Accelerator Center; DOE IP
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options